Forebyggelse af reaktivering af hepatitis B og hepatitis C ved immunsupprimerende behandling

Malene Risum, Toke Seierøe Barfod

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstrakt

The use of immunosuppressive agents can be vital. However, immunosuppression may also cause reactivation of hepatitis B virus (HBV) infection which can be fatal. To reduce the risk of reactivation prophylactic antiviral treatment is recommended in patients with chronic HBV infection. In patients with former HBV infection prophylaxis is also recommended if anti-CD20 agents are used and in cases of transplantation. Immunosuppression in patients with hepatitis C virus (HCV) infection does not seem to lead to severe hepatic manifestations, and reactivation of HCV in this context generally has a mild clinical course.

Bidragets oversatte titelProphylaxis of reactivation of hepatitis B and hepatitis C virus infection in immunosuppressive therapy
OriginalsprogDansk
ArtikelnummerV08180568
Sider (fra-til)2048-2051
Antal sider4
TidsskriftUgeskrift for Laeger
Vol/bind181
Udgave nummer21
StatusUdgivet - 4 feb. 2019

Fingeraftryk

Udforsk hvilke forskningsemner 'Forebyggelse af reaktivering af hepatitis B og hepatitis C ved immunsupprimerende behandling' indeholder.

Citationsformater